Z-Toremifene

Z-Toremifene Brand names, Z-Toremifene Analogs

Z-Toremifene Brand Names Mixture

No information avaliable

Z-Toremifene Chemical_Formula

C₂₆H₂₈ClNO

Z-Toremifene RX_link

http://www.rxlist.com/cgi/generic2/toremifene.htm

Z-Toremifene fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=151

Z-Toremifene msds (material safety sheet)

Z-Toremifene Synthesis Reference

R. J. Toivola et al., Eur. pat. Appl. 95,875; U.S. pat. 4,696,949 (1983, 1087 both to Farmos)

Z-Toremifene Molecular Weight

405.959 g/mol

Z-Toremifene Melting Point

108-110 ^oC

Z-Toremifene H₂O Solubility

No information avaliable

Z-Toremifene State

Solid

Z-Toremifene LogP

6.725

Z-Toremifene Dosage Forms

Tablet

Z-Toremifene Indication

For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors

Z-Toremifene Pharmacology

Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein.

Z-Toremifene Absorption

Well absorbed

Z-Toremifene side effects and Toxicity